CA3024434A1 - Methods for reducing oxidative damage - Google Patents

Methods for reducing oxidative damage

Info

Publication number
CA3024434A1
CA3024434A1 CA3024434A CA3024434A CA3024434A1 CA 3024434 A1 CA3024434 A1 CA 3024434A1 CA 3024434 A CA3024434 A CA 3024434A CA 3024434 A CA3024434 A CA 3024434A CA 3024434 A1 CA3024434 A1 CA 3024434A1
Authority
CA
Canada
Prior art keywords
phe
pharmaceutical composition
use according
arg
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3024434A
Other languages
English (en)
French (fr)
Inventor
Hazel H. Szeto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell Research Foundation Inc
Original Assignee
Cornell Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell Research Foundation Inc filed Critical Cornell Research Foundation Inc
Publication of CA3024434A1 publication Critical patent/CA3024434A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
CA3024434A 2004-01-23 2005-01-21 Methods for reducing oxidative damage Abandoned CA3024434A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53884104P 2004-01-23 2004-01-23
US60/538841 2004-01-23
CA2971931A CA2971931C (en) 2004-01-23 2005-01-21 Methods for reducing oxidative damage

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2971931A Division CA2971931C (en) 2004-01-23 2005-01-21 Methods for reducing oxidative damage

Publications (1)

Publication Number Publication Date
CA3024434A1 true CA3024434A1 (en) 2005-08-11

Family

ID=34826019

Family Applications (7)

Application Number Title Priority Date Filing Date
CA3024434A Abandoned CA3024434A1 (en) 2004-01-23 2005-01-21 Methods for reducing oxidative damage
CA2971928A Expired - Lifetime CA2971928C (en) 2004-01-23 2005-01-21 Methods for reducing oxidative damage
CA2971931A Expired - Lifetime CA2971931C (en) 2004-01-23 2005-01-21 Methods for reducing oxidative damage
CA2971929A Expired - Lifetime CA2971929C (en) 2004-01-23 2005-01-21 Methods for reducing oxidative damage
CA2887797A Expired - Lifetime CA2887797C (en) 2004-01-23 2005-01-21 Methods for reducing oxidative damage
CA2554166A Expired - Lifetime CA2554166C (en) 2004-01-23 2005-01-21 Methods for reducing oxidative damage
CA2851972A Expired - Lifetime CA2851972C (en) 2004-01-23 2005-01-21 Methods for reducing oxidative damage

Family Applications After (6)

Application Number Title Priority Date Filing Date
CA2971928A Expired - Lifetime CA2971928C (en) 2004-01-23 2005-01-21 Methods for reducing oxidative damage
CA2971931A Expired - Lifetime CA2971931C (en) 2004-01-23 2005-01-21 Methods for reducing oxidative damage
CA2971929A Expired - Lifetime CA2971929C (en) 2004-01-23 2005-01-21 Methods for reducing oxidative damage
CA2887797A Expired - Lifetime CA2887797C (en) 2004-01-23 2005-01-21 Methods for reducing oxidative damage
CA2554166A Expired - Lifetime CA2554166C (en) 2004-01-23 2005-01-21 Methods for reducing oxidative damage
CA2851972A Expired - Lifetime CA2851972C (en) 2004-01-23 2005-01-21 Methods for reducing oxidative damage

Country Status (13)

Country Link
US (8) US7550439B2 (enExample)
EP (1) EP1722807A4 (enExample)
JP (1) JP4931604B2 (enExample)
KR (1) KR101159254B1 (enExample)
CN (1) CN1938042B (enExample)
AU (1) AU2005208821B8 (enExample)
BR (1) BRPI0507053A (enExample)
CA (7) CA3024434A1 (enExample)
IL (5) IL177030A (enExample)
NZ (1) NZ549393A (enExample)
RU (1) RU2376028C2 (enExample)
WO (1) WO2005072295A2 (enExample)
ZA (1) ZA200607013B (enExample)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2656854T1 (sl) * 2003-02-04 2015-09-30 Cornell Research Foundation, Inc. Uporabe aromatsko-kationskega peptida
EP3167935B1 (en) 2003-05-01 2018-07-18 Cornell Research Foundation, Inc. Method and carrier complexes for delivering molecules to cells
CA3024434A1 (en) 2004-01-23 2005-08-11 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
US8822542B2 (en) 2004-10-20 2014-09-02 Vanderbilt University Isoketal scavengers and mitigation of disorders involving oxidative injury
GB0517090D0 (en) * 2005-08-19 2005-09-28 Tcp Innovations Ltd ApoE mimetic agents
AU2014203126B2 (en) * 2005-09-16 2016-03-10 Cornell Research Foundation, Inc. Methods for reducing cd36 expression
AU2019257440B2 (en) * 2005-09-16 2021-12-16 Cornell Research Foundation, Inc. Methods for reducing CD36 expression
EP3725324A1 (en) * 2005-09-16 2020-10-21 Cornell Research Foundation, Inc. Aromatic-cationic peptide for use in a method for reducing cd36 expression
JP5236641B2 (ja) 2006-07-25 2013-07-17 ハフ イヤ インスティテュート 急性音響外傷の治療方法
US8389482B2 (en) 2007-01-30 2013-03-05 New York University Short peptides useful for treatment of ischemia/reperfusion injury and other tissue damage conditions associated with nitric oxide and its reactive species
JP4461159B2 (ja) * 2007-06-14 2010-05-12 ヤマハファインテック株式会社 プリント基板の検査装置および検査方法
EP2712620A1 (en) 2008-02-07 2014-04-02 Cornell University Methods for Preventing or Treating Insulin Resistance
CN107802821A (zh) * 2008-02-26 2018-03-16 康奈尔大学 用于防止和治疗急性肾损伤的方法
DE102008061044A1 (de) * 2008-12-11 2010-06-17 Henkel Ag & Co. Kgaa Zusammensetzung mit antioxidativ wirksamen Peptiden
EP3563862B1 (en) * 2009-03-20 2021-05-05 The General Hospital Corporation d/b/a Massachusetts General Hospital D-arg-2'6'-dimethyltyrosine-lys-phe-nh2 for use in the prevention of secondary complications of burn injuries
EP2477594A4 (en) * 2009-07-15 2013-03-13 Univ Vanderbilt ISOKETAL CATCHER AND TREATMENT OF DISEASES WITH OXIDATIVE INJURY
CA2770688C (en) * 2009-08-12 2018-06-05 Cornell University Methods for preventing or treating metabolic syndrome
SI3708178T1 (sl) * 2009-08-24 2024-01-31 Stealth Biotherapeutics Inc. Peptid za uporabo pri preprečevanju ali zdravljenju degeneracije makule
EP3603658B1 (en) 2009-10-05 2025-01-08 Cornell University Peptide for use in the treatment of heart failure resulting from hypertrophic cardiomyopathy
TWI535440B (zh) * 2009-10-26 2016-06-01 Ｌｇ生命科學有限公司 包括吲哚化合物之醫藥組成物
US20130195837A1 (en) * 2009-12-31 2013-08-01 Stealth Peptides International, Inc. Methods for the prevention or treatment of vessel occlusion injury
EP2519249A4 (en) * 2009-12-31 2013-06-26 Stealth Peptides Int Inc METHOD FOR CARRYING OUT A CORONARY ARTERY BYPASS PROCEDURE
CA2787331A1 (en) * 2010-01-25 2011-07-28 Hazel H. Szeto Aromatic-cationic peptides and uses of same
EP3332795A1 (en) * 2010-02-26 2018-06-13 Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
EP2808029A3 (en) 2010-03-15 2015-04-01 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
US20110245182A1 (en) * 2010-04-06 2011-10-06 Perricone Nicholas V Topical Uses of Szeto-Schiller Peptides
US20110245183A1 (en) * 2010-04-06 2011-10-06 Perricone Nicholas V Topical Uses of Szeto-Schiller Peptides
JP2013532124A (ja) * 2010-05-03 2013-08-15 ステルス ペプチドズ インターナショナル インコーポレイテッド 芳香族系陽イオンペプチド及びその使用
HUP1000243A2 (en) 2010-05-06 2012-01-30 Avidin Kft 8-hidroxy-quinoline derivatives
CN103249423A (zh) 2010-07-09 2013-08-14 康肽德生物医药技术有限公司 预防或治疗缺血/再灌注损伤之后无复流的方法
US20130288985A1 (en) * 2010-07-15 2013-10-31 The Schepens Eye Research Institute Inc. Compositions and methods of treatment of corneal endothelium disorders
KR20130096731A (ko) 2010-09-08 2013-08-30 할로자임, 아이엔씨 조건부 활성 치료적 단백질을 평가，확인 또는 진화시키는 방법
US20120083452A1 (en) * 2010-09-30 2012-04-05 Perricone Nicholas V Topical Anesthetic Uses of Szeto-Schiller Peptides
WO2012106654A1 (en) 2011-02-04 2012-08-09 Hough Ear Institute Methods for treating brain injury
CA2839408A1 (en) * 2011-06-14 2012-12-20 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
CN102327600A (zh) * 2011-09-14 2012-01-25 中国人民解放军军事医学科学院放射与辐射医学研究所 用于预防和治疗辐射损伤的rx31肽
CN107496899A (zh) * 2011-09-29 2017-12-22 梅约医学教育与研究基金会 芳族阳离子肽和使用它们的方法
CN107261380A (zh) * 2011-10-17 2017-10-20 康奈尔大学 芳香族阳离子肽及其用途
HK1204988A1 (en) 2012-02-22 2015-12-11 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions
CA2865409C (en) * 2012-02-23 2020-07-21 Cornell University Aromatic-cationic peptides and uses of same
CA2866612C (en) 2012-03-08 2018-01-16 Halozyme, Inc. Conditionally active ph-dependent cetuximab variant anti-epidermal growth factor receptor antibodies and method of use thereof
CA2869080C (en) 2012-03-30 2020-09-01 Stealth Peptides International, Inc. Methods and compositions for the prevention and treatment neuropathy
US10793597B2 (en) * 2013-03-01 2020-10-06 Stealth Biotherapeutics Corp Methods for the treatment of mitochondrial diseases associated with a mutation in SURF 1 or POLG gene resulting in a disruption of mitochondrial oxidative phosphorylation
EP3626252A1 (en) 2013-03-01 2020-03-25 Stealth Biotherapeutics Corp Methods and compositions for the prevention or treatment of barth syndrome
US10047395B2 (en) 2013-06-26 2018-08-14 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
CA2916497C (en) * 2013-06-26 2022-07-12 Stealth Biotherapeutics Corp Methods for the regulation of matrix metalloproteinase expression
CA2920020C (en) 2013-08-02 2023-03-14 Stealth Biotherapeutics Corp Methods and compositions for the prevention and treatment of friedreich's ataxia
CN106102760A (zh) * 2013-09-27 2016-11-09 康奈尔大学 芳香族阳离子肽用于治疗胆固醇诱发的线粒体功能障碍的用途
CA2925757A1 (en) * 2013-09-30 2015-04-02 Cornell University Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity
EP3060573B1 (en) 2013-10-23 2019-07-17 Kaneka Corporation Tetrapeptide compound and method for producing same
CA2932408A1 (en) * 2013-12-02 2015-06-11 Stealth Biotherapeutics Corp Compositions and methods for treating vitiligo
EP3082838A4 (en) * 2013-12-16 2017-07-26 Cornell University Methods and compositions for treating and preventing cognitive dysfunction
EP3071591B1 (en) * 2014-01-22 2021-05-05 Agency For Science, Technology And Research Antimicrobial peptidomimetics
US9314457B2 (en) 2014-06-19 2016-04-19 The University Of Utah Research Foundation Methods of treating and preventing vascular instability diseases
HUE054626T2 (hu) 2014-06-25 2021-09-28 Flamma Spa Eljárás D-arginil-2,6-dimetil-L-tirozil-L-lizil-L-fenilalaninamid elõállítására
PL3160985T3 (pl) 2014-06-30 2021-12-27 Flamma S.P.A. Sposób wytwarzania d-arginylo-2,6-dimetylo-l-tyrozylo-l-lizylo-l-fenyloalaninoamidu
WO2016004093A2 (en) * 2014-07-01 2016-01-07 Stealth Biotherapeutics Corp Therapeutic compositions including galectin-3 inhibitors and uses thereof
WO2016200364A1 (en) * 2015-06-08 2016-12-15 Stealth Peptides International, Inc. THERAPEUTIC COMPOSITIONS INCLUDING SkQ COMPOUNDS AND USES THEREOF
WO2017070421A1 (en) * 2015-10-22 2017-04-27 The Feinstein Institute For Medical Research Use of dermcidin in sterile inflammatory conditions
WO2017093897A1 (en) * 2015-11-30 2017-06-08 Peter Schiller Aromatic-cationic peptides conjugated to antioxidants and their use in treating complex regional pain syndrome
RU2613910C1 (ru) * 2015-12-08 2017-03-21 Федеральное государственное бюджетное учреждение науки Государственный научный центр Российской Федерации - Институт медико-биологических проблем Российской академии наук (ГНЦ РФ - ИМБП РАН) Способ определения тканевой гипоксии скелетных мышц и миокарда при гиподинамии
US20170224764A1 (en) * 2016-02-10 2017-08-10 Cornell University Therapeutic targeting of mitochondria to prevent osteoarthritis
CN107041946A (zh) * 2017-03-24 2017-08-15 南京大学 化合物ss‑31在制备治疗动脉粥样硬化及相关疾病药物或制剂上的应用
US20210206805A1 (en) * 2018-05-23 2021-07-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Cardiac-specific targeting-peptide (ctp), compositions, and uses thereof
JP7867990B2 (ja) * 2020-07-09 2026-06-01 ムスク・ファウンデイション・フォー・リサーチ・ディベロップメント 傷害から細胞を保護する方法
US11389431B2 (en) 2020-09-09 2022-07-19 Social Profit Network Methods and compositions for delivery of biotin to mitochondria
CN117881411A (zh) 2021-06-01 2024-04-12 艾迪雅生物有限责任公司 用于眼部药物的延长释放药物递送系统和使用方法
CN114773433B (zh) * 2022-06-23 2022-09-06 北京肿瘤医院(北京大学肿瘤医院) 一种cd25靶向多肽、分子探针及应用
GB2630566A (en) * 2023-05-22 2024-12-04 Jaguar Land Rover Ltd Apparatus and method for controlling an actuator

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
SG64368A1 (en) 1988-06-30 1999-04-27 Astra Ab Dermorphin analogs their methods of preparation pharmaceutical compositions and methods of therapeutic treatment using the same
US5602100A (en) 1988-06-30 1997-02-11 Astra Ab Dermorphin analogs having pharmacological activity
US5118670A (en) * 1988-12-14 1992-06-02 Massachusetts Institute Of Technology Process and composition for increasing brain dopamine release
US5670617A (en) 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
IS4261A (is) 1994-02-21 1995-08-22 Astra Aktiebolag Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra
EP0747092B1 (en) * 1995-06-09 2003-12-03 Hisamitsu Pharmaceutical Co., Inc. Matrix for iontophoresis
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
CA2270661A1 (en) * 1996-10-07 1998-04-16 Lawrence Joseph Heinz Novel compounds useful as neuro-protective agents
RU2115660C1 (ru) * 1997-01-28 1998-07-20 Институт биоорганической химии им.М.М.Шемякина и Ю.А.Овчинникова РАН Пептиды, обладающие антистрессорным, противосудорожным и нейропротекторным действием
US5885958A (en) 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
CA2314267A1 (en) 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
US6417210B1 (en) * 1998-01-09 2002-07-09 Mor-Research Applications Ltd. Treatment of dyskinesias and Parkinson's disease with riluzole and levodopa
US6268398B1 (en) 1998-04-24 2001-07-31 Mitokor Compounds and methods for treating mitochondria-associated diseases
US6472378B2 (en) 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
SE9900961D0 (sv) 1999-03-16 1999-03-16 Astra Ab Novel compounds
US6503713B1 (en) 1999-10-04 2003-01-07 University Of Medicine And Dentistry Of New Jersey Methods for identifying RNA binding compounds
US6759520B1 (en) * 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US20050192215A1 (en) 2000-01-21 2005-09-01 Malabika Ghosh Methods and materials relating to novel polypeptides and polynucleotides
ATE496533T1 (de) * 2000-07-18 2011-02-15 Cornell Res Foundation Inc Medizinische verwendung von agonisten des mu- opioid rezeptors
US6900178B2 (en) 2000-09-12 2005-05-31 University Of Kentucky Research Foundation Protection against ischemia and reperfusion injury
AU2002225767A1 (en) 2000-11-28 2002-06-11 Guilford Pharmaceuticals Inc. Bisubstituted carbocyclic cyclophilin binding compounds and theirus
MXPA03006666A (es) 2001-01-25 2004-05-31 Guilford Pharm Inc Compuestos de union de ciclofilina carbociclicos trisubstituidos y su uso.
US20030077826A1 (en) 2001-02-02 2003-04-24 Lena Edelman Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC)
SI2656854T1 (sl) 2003-02-04 2015-09-30 Cornell Research Foundation, Inc. Uporabe aromatsko-kationskega peptida
EP3167935B1 (en) * 2003-05-01 2018-07-18 Cornell Research Foundation, Inc. Method and carrier complexes for delivering molecules to cells
US7232824B2 (en) 2003-09-30 2007-06-19 Scios, Inc. Quinazoline derivatives as medicaments
CA3024434A1 (en) * 2004-01-23 2005-08-11 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
EP3725324A1 (en) 2005-09-16 2020-10-21 Cornell Research Foundation, Inc. Aromatic-cationic peptide for use in a method for reducing cd36 expression

Also Published As

Publication number Publication date
ZA200607013B (en) 2008-01-08
CA2971929C (en) 2019-01-08
US8618061B2 (en) 2013-12-31
CA2887797C (en) 2017-09-26
CA2554166C (en) 2014-07-29
WO2005072295A2 (en) 2005-08-11
CA2554166A1 (en) 2005-08-11
CA2851972C (en) 2015-06-23
IL235772A (en) 2016-12-29
EP1722807A2 (en) 2006-11-22
KR20070003872A (ko) 2007-01-05
US20190328821A1 (en) 2019-10-31
RU2376028C2 (ru) 2009-12-20
IL237407A0 (en) 2015-04-30
NZ549393A (en) 2009-07-31
AU2005208821B2 (en) 2010-09-30
CA2971931C (en) 2019-01-08
EP1722807A4 (en) 2010-09-15
HK1102289A1 (zh) 2007-11-16
JP4931604B2 (ja) 2012-05-16
US9950026B2 (en) 2018-04-24
US20160317604A1 (en) 2016-11-03
WO2005072295A3 (en) 2005-09-29
AU2005208821A1 (en) 2005-08-11
BRPI0507053A (pt) 2007-06-12
IL256703A (en) 2018-03-29
CA2971931A1 (en) 2005-08-11
IL177030A (en) 2015-04-30
CA2971928C (en) 2019-01-08
US20140349942A1 (en) 2014-11-27
AU2005208821B8 (en) 2010-10-14
CN1938042B (zh) 2010-06-02
IL237408B (en) 2019-03-31
US20230149501A1 (en) 2023-05-18
US7781405B2 (en) 2010-08-24
IL256703B (en) 2020-11-30
CA2971928A1 (en) 2005-08-11
US20060084606A1 (en) 2006-04-20
US20070015711A1 (en) 2007-01-18
AU2005208821A2 (en) 2005-08-11
US20210015887A1 (en) 2021-01-21
US20100311664A1 (en) 2010-12-09
RU2006130431A (ru) 2008-02-27
KR101159254B1 (ko) 2012-06-26
JP2007518818A (ja) 2007-07-12
CA2851972A1 (en) 2005-08-11
US9623069B2 (en) 2017-04-18
IL237408A0 (en) 2015-04-30
US7550439B2 (en) 2009-06-23
CA2971929A1 (en) 2005-08-11
CN1938042A (zh) 2007-03-28
IL177030A0 (en) 2006-12-10
CA2887797A1 (en) 2005-08-11
IL237407B (en) 2018-07-31

Similar Documents

Publication Publication Date Title
CA2971928C (en) Methods for reducing oxidative damage
US20250263433A1 (en) Methods for reducing cd36 expression
CA2515080C (en) Methods for preventing mitochondrial permeability transition
MXPA06008342A (en) Methods for reducing oxidative damage
HK1102289B (en) Use of an aromatic cationic peptide in preparing the medicaments for reducing oxidative damage
HK1204999B (en) Methods for preventing mitochondrial permeability transition
HK1174643A (en) Methods for preventing mitochondrial permeability transition
HK1131995B (en) Methods for preventing mitochondrial permeability transition

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20181116

FZDE Discontinued

Effective date: 20230208